Data obtained retrospectively from a group of patients with chronic granulocytic leukemia provided the basis for characterizing the onset of the terminal phase of chronic granulocytic leukemia. Such characterization permits an opportunity to introduce in sufficient time new therapeutic agents for the treatment of a phase of a disease which heretofore has been refractory to conventional therapy. The suggested criteria marking the onset of the terminal phase may require revision as more information is systematically collected in the future.

This content is only available as a PDF.
© 1968 by American Society of Hematology, Inc.
1968
Sign in via your Institution